Vertex’s KALYDECO (ivacaftor) Receives FDA Approval for Treatment of Cystic Fibrosis in…
Vertex Pharmaceuticals Incorporated announced the U.S. Food and Drug Administration (FDA) approved KALYDECO (ivacaftor) for use in children with cystic fibrosis (CF) ages 1 month to…
Read More...
Read More...